Pharmaceutical composition for treating burns and scalds as well as preparation method and application of pharmaceutical composition
By using pharmaceutical compositions of rhubarb, rhubarb, elm, elm, elm, elm, elm, elm and borneol, the problem of poor effectiveness in the treatment of burns and scalds is solved, and significant antibacterial, pain-relieving and healing effects are achieved, and there are relatively small adverse reactions.
Patent Information
- Application Number
- CN202510016841.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-01-06
- Publication Date
- 2025-03-25
AI Technical Summary
The prior art has problems with poor therapeutic effects and adverse drug reactions in the treatment of burns and scalds, and traditional drugs have limited effectiveness in improving scar tissue texture.
A pharmaceutical composition, including rhubarb, rhubarb, elm, elm, elm charcoal, elm charcoal, elm cinu and borneol, is grinded into powder in a specific proportion and prepared with sesame oil to form a thick paste for direct application to burn wound surface.
The pharmaceutical composition showed positive effects in antibacterial, pain relief, antiseptic, freshness-preserving, promoting skin healing and growth of new tissues. Animal experiments showed that it had significant therapeutic effect on burn-scald mouse models and was highly safe.
Smart Images
Figure CN119679861A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a Chinese medicine composition, in particular to a medicine composition for treating burns and scalds, and a preparation method and application thereof. Background Art
[0002] Burns are a very common skin injury, usually caused by skin contact with high temperature or chemical substances. Burns may occur in various situations, whether in daily life or war, and will cause patients considerable pain. Burns are often accompanied by severe pain and a long treatment period, which not only causes physical harm to patients, but may also have long-term psychological effects on individuals.
[0003] Modern medicine treats burns by using antibiotics and eliminating inflammation, but some drugs have many adverse reactions and disadvantages. In comparison, traditional Chinese medicine has certain advantages in treating burns. For example, some Chinese medicine preparations can stimulate angiogenesis, improve microcirculation, provide more nutrients and oxygen to the burn wound and promote wound healing. Most Chinese medicines come from natural plants, animals or minerals, and their side effects are relatively small. Compared with Western medicine, the use of Chinese medicine to treat burns generally does not cause obvious adverse reactions, has less burden on the patient's body, and is suitable for long-term treatment. In addition, some Chinese medicine external preparations have the effects of promoting blood circulation and removing blood stasis, softening and dispersing nodules, and reducing swelling and relieving pain. After use, not only the pain is relieved, but also the texture of scar tissue can be effectively improved, making the recovery closer to normal skin. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a new pharmaceutical composition for treating burns and scalds, and a preparation method and application thereof, so as to improve the therapeutic effect of burns and scalds.
[0005] To solve the above technical problems, according to one aspect of the present invention, a pharmaceutical composition for treating burns and scalds is provided, wherein the raw materials include 10-30 parts of rhubarb, 10-30 parts of rhubarb charcoal, 10-30 parts of sanguisorba officinalis, 10-30 parts of sanguisorba officinalis charcoal, 10-30 parts of aconite, and 0.5-1.5 parts of borneol, in parts by mass.
[0006] Furthermore, the raw materials include, by weight, 15-25 parts of rhubarb, 15-25 parts of rhubarb charcoal, 15-25 parts of sanguisorba officinalis, 15-25 parts of sanguisorba officinalis charcoal, 15-25 parts of aconite, and 0.8-1.2 parts of borneol.
[0007] Furthermore, in terms of mass, the raw materials include 20 parts of rhubarb, 20 parts of rhubarb charcoal, 20 parts of sanguisorba officinalis, 20 parts of sanguisorba officinalis charcoal, 20 parts of aglaonema, and 1 part of borneol.
[0008] According to another aspect of the present invention, provided is a method for preparing the above-mentioned pharmaceutical composition for treating burns and scalds, comprising the following steps: Weigh rhubarb, rhubarb charcoal, sanguisorba officinalis, sanguisorba officinalis charcoal, aconite and borneol according to proportion, grind into powder; add auxiliary materials to make a thick paste.
[0009] Furthermore, the auxiliary material is sesame oil.
[0010] According to another aspect of the present invention, the pharmaceutical composition for treating burns and scalds is used in preparing medicines for treating burns and scalds.
[0011] According to another aspect of the present invention, the pharmaceutical composition for treating burns and scalds is used in the preparation of a drug for promoting the healing of burn and scald wounds.
[0012] The pharmaceutical composition of the present invention has positive effects in antibacterial and analgesic effects, antiseptic and preservation, and promotion of skin healing and growth of new tissues. Animal experimental results show that JRO has a good therapeutic effect on burn and scald mouse models and has good safety. Network pharmacology confirms the overall regulatory effect of JRO with multiple components and multiple targets. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 middle, Figure 1 A is a graph showing the changes of the burn wound surface over time after JRO was applied to the wound surface. Figure 1 B. Figure 1 C shows the changes in the healing rate of burn wounds in each group.
[0014] Figure 2 This is the HE staining picture of burned and scalded mice skin; Figure 3 These are the blood biochemical indicators of mice with burns; Figure 4 This is a diagram showing the histological observation of organs in mice with burns. DETAILED DESCRIPTION
[0015] A typical embodiment of the present invention provides a pharmaceutical composition for treating burns and scalds (JinuRhubarb Ointment), hereinafter referred to as JRO, which comprises, by weight, 10-30 parts of rhubarb, 10-30 parts of rhubarb charcoal, 10-30 parts of sanguisorba officinalis, 10-30 parts of sanguisorba officinalis charcoal, 10-30 parts of aconite, and 0.5-1.5 parts of borneol.
[0016] Preferably, the raw materials of the pharmaceutical composition include 15-25 parts of rhubarb, 15-25 parts of rhubarb charcoal, 15-25 parts of sanguisorba officinalis, 15-25 parts of sanguisorba officinalis charcoal, 15-25 parts of amaranth, and 0.8-1.2 parts of borneol. Further preferably, the raw materials include 20 parts of rhubarb, 20 parts of rhubarb charcoal, 20 parts of sanguisorba officinalis, 20 parts of sanguisorba officinalis charcoal, 20 parts of amaranth, and 1 part of borneol.
[0017] The pharmaceutical composition provided in this embodiment mainly consists of rhubarb, rhubarb charcoal, sanguisorba officinalis, sanguisorba officinalis charcoal, ligustrum lucidum and borneol, and sesame oil is used as an auxiliary material to be blended into a paste. The sesame oil, also called sesame oil, can be sesame oil or sesame oil.
[0018] When using, apply the prepared thick paste to the affected area without covering it with gauze.
[0019] The rhubarb, sanguisorba officinalis and achyranthes bidentata in the formula have anti-inflammatory, antibacterial, wound healing and tissue repair effects.
[0020] Rhubarb charcoal and Sanguisorba officinalis charcoal are prepared by charcoal frying. The methods are as follows: take rhubarb slices, separate them by size, put them in a hot pot, fry them with high heat (180~220℃) until the surface is burnt black and the inside is burnt brown, spray a little water, extinguish the sparks, take them out, and let them cool. Take Sanguisorba officinalis slices, put them in a wok, fry them with high heat until the surface of the medicine is burnt black and the inside is brown, take them out, and let them cool. Compared with the original rhubarb and Sanguisorba officinalis, the content of some chemical components in the processed Chinese medicine has changed, and the ability to astringe and stop bleeding is more prominent.
[0021] Borneol is antiseptic, anti-itching and analgesic, and can very effectively relieve the patient's pain during the treatment process.
[0022] The above-mentioned pharmaceutical composition uses multi-component, multi-target and multi-pathway interactions to exert its efficacy, and has positive effects in antibacterial and analgesic, antiseptic and freshness preservation, and promoting skin healing and the growth of new tissues.
[0023] The technical scheme claimed in the present invention is further described below by some examples. However, the examples are used to explain the embodiments of the present invention and do not exceed the scope of the subject matter of the present invention. The protection scope of the present invention is not limited by the examples. Unless otherwise specified, the materials and reagents used in the present invention can be obtained from commercial products in the art. Example 1
[0024] Raw material composition: 20g of rhubarb, 20g of rhubarb charcoal, 20g of sanguisorba officinalis, 20g of sanguisorba officinalis charcoal, 20g of lily of the valley, and 1 part of borneol. Grind the above raw materials into powder and mix them into a thick paste with sesame oil. Example 2
[0025] Raw material composition: 10g of rhubarb, 10g of rhubarb charcoal, 10g of sanguisorba officinalis, 10g of sanguisorba officinalis charcoal, 10g of lily of the valley, and 0.5g of borneol. Grind the above raw materials into powder and mix them into a thick paste with sesame oil. Example 3
[0026] Raw material composition: 10g of rhubarb, 10g of rhubarb charcoal, 10g of sanguisorba officinalis, 10g of sanguisorba officinalis charcoal, 10g of lily of the valley, and 1.5g of borneol. Grind the above raw materials into powder and mix into a thick paste with sesame oil. Example 4
[0027] Raw material composition: 10g of rhubarb, 30g of rhubarb charcoal, 20g of sanguisorba officinalis, 15g of sanguisorba officinalis charcoal, 25g of lily of the valley, and 1g of borneol. Grind the above raw materials into powder and mix them into a thick paste with sesame oil.
[0028] The present invention uses animal experiments to demonstrate the therapeutic effect and adopts the research method of network pharmacology to study the mechanism of action of JRO. At the same time, molecular docking is used to further verify its mechanism, providing a reference for the research on the target of JRO in treating burns and scalds and its wider clinical application.
[0029] 1. Evaluation of the effect of JRO in treating burn wounds 1.1 Establishment of mouse burn model Female KM mice were anesthetized with tribromoethanol, and the hair on the back of the mice was shaved. After the skin was exposed, a stainless steel column (1.6 cm in diameter and 240 g in weight) preheated to 100°C was placed in contact with the skin for 10 seconds (no external force was applied to the stainless steel column to ensure that each burn was caused by similar pressure each time). All mice were randomly divided into five groups: control group (no treatment), model group (wounds were treated with normal saline), JRO intervention group, auxiliary material group (JRO auxiliary material was sesame oil, so sesame oil was selected as the treatment method for the auxiliary material group), and positive drug group (Moist Exposed Burn Ointment, MEBO, which has a good effect on treating burns on the market, was selected). Except for the control group with 3 mice, there were 9 mice in each group. Each group of mice was given the drug once a day. Before the drug was given, the wound was rinsed with normal saline, and then the corresponding drug of each group was evenly applied to cover the wound for 15 days. The wound was photographed every 3 days, and the long and short diameters of the burn wound were measured with a vernier caliper every 2 days to calculate the area (since the burn wound was burned with a metal cylinder, the area was approximately calculated as an ellipse), and the wound healing rate was calculated (wound healing rate (%) = (original wound area - unhealed wound area) / original wound area × 100%).
[0030] The effects of saline, JRO, sesame oil and MEBO on the healing of burn wounds in mice were evaluated. Applying JRO to the wound surface significantly reduced the size of the burn wound compared with the other groups ( Figure 1A). Compare the burn wound healing rates of different groups and the model group on different treatment days. Figure 1 As shown in B, no significant changes were found on the 5th day in each group (P>0.05), but on the 7th and 9th days, the healing rates of the back burn wounds in the mice treated with JRO and MEBO were significantly different from those in the model group (P<0.05), and on the 7th day, the healing rates of the burn wounds in the JRO treatment group were more significantly different from those in the MEBO group (P<0.01). The overall healing rates of the JRO and MEBO groups were significantly higher than those of the other two groups. Figure 1 C. It can be seen that JRO has a good effect in promoting the healing of burn wounds in mice.
[0031] 1.2 Histological analysis by HE staining In addition to the control group, the other four groups were randomly divided into three subgroups. Every five days, mice in each group were killed by cervical dislocation (all killing processes strictly followed the Animal Ethics Protection Act), and then the back burned skin tissue was taken for HE skin staining. The results are shown in Figure 2. Figure 2 shown.
[0032] On the 5th day of medication, a small amount of hair grew around the burn wound, and a small part of the scab lifted up. Epithelial cell growth was rare in the model group and the auxiliary material group, while the number of capillaries in the JRO group and the MEBO group increased slightly, and some epithelial growth was clearly visible. In general, the JRO and MEBO groups were better than the other two groups.
[0033] On the 10th day of medication, obvious hair growth appeared on the burn wound surface, and the scab area was significantly reduced. Epithelial cell growth and increased number of capillaries were observed in the model group and the auxiliary material group. Epithelial growth was more obvious in the JRO and MEBO groups, and the wound area was significantly reduced. Compared with the other two groups, epithelial cell migration in the wound of the JRO and MEBO groups increased, re-epithelialization was significantly better, and the granulation tissue was well-developed and healthy.
[0034] On the 15th day after medication, the wounds were basically healed, and the scabs in the JRO and MEBO groups were basically gone, while a small part of the scabs in the model and auxiliary material groups remained unhealed. Smaller areas of scar tissue appeared in the JRO and MEBO groups after healing, and the healing situation was better than that in the other two groups.
[0035] 2. JRO Security Assessment 2.1 Blood biochemical analysis Under the same feeding environment, the mice in the control group and the last treated group in each large group were killed on the 15th day, and blood was quickly collected from the eye sockets. The collected specimens were then placed in a 4°C refrigerator for 30 minutes, centrifuged at 3000 rpm for 15 minutes, and the upper serum was collected for blood biochemical analysis.
[0036] like Figure 3 As shown in the figure, the burned mice were treated with JRO for 15 consecutive days. There was no statistically significant difference in the blood biochemical indexes between the JRO group and the blank group ( P＞0.05 ).
[0037] 2.2 Histological observation of organs in mice with burns after external application of JRO After 15 days of continuous medication, the burned mice in different treatment groups showed good morphology, the back burn wounds were basically healed, a large number of hair shafts in the depilated area had regrown, and after dissection, the surfaces of the heart, liver, spleen, lungs, kidneys, thymus and other organs were smooth and no abnormal lesions were found. The dissection results showed that the appearance and color of the organ tissues were normal. Figure 4 As shown, under tissue section observation, there was no pathological damage to the tissue structure of each organ.
[0038] 3. Network Pharmacology Analysis The chemical components and targets of all Chinese medicines in the JRO formula were searched from the TCMSP system pharmacology analysis platform to construct a compound-target interaction network diagram. Burn disease-related targets were retrieved and obtained through the human comprehensive gene database Gene Cards, OMIM and TTD database, and then a disease-target relationship network diagram was constructed. Finally, Gene Ontology (GO) biological process enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the key targets of JRO for the treatment of burns and scalds through the DAVID database, and molecular docking was performed using AutoDockTools 1.5.7.
[0039] Network pharmacology screened out 23 different effective active ingredients in 4 drugs in JRO, GO analysis obtained a total of 627 enrichment results, and the KEGG database was used to enrich the selected targets for related pathways, and a total of 145 pathway enrichment results were obtained. Molecular docking results showed that quercetin, baicalein, kaempferol, β-sitosterol, aloe-emodin, and oleanolic acid all had good affinity for the top five targets in the PPI network, TNF, AKT1, IL1B, TP53, and MMP9.
[0040] Compound TNF AKT1 IL1B TP53 MMP9 β-Sitosterol -6.5 -6.8 -6.7 -9.2 -8.3 Baicalin -8.6 -6.4 -7.4 -9.2 -8 Quercetin -7.8 -6.2 -7.2 -8.9 -7.9 Aloe-emodin -6.6 -6.9 -6.8 -8.7 -7.7 Oleanolic acid -7.7 -7.3 -7.5 -9.8 -8.9 Kaempferol -8.6 -6 -7.2 -8.8 -7.5 This indicates that these six compounds can bind well to the core receptor protein, thereby exerting a therapeutic effect on burns and scalds.
[0041] The scope of protection claimed by the present invention is not limited to the above specific embodiments. For those skilled in the art, the present invention may have various deformations and changes. Any modifications, improvements and equivalent substitutions made within the concept and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A pharmaceutical composition for treating burns and scalds, characterized in that: Calculated by weight, the raw materials include 10-30 parts of rhubarb, 10-30 parts of rhubarb charcoal, 10-30 parts of sanguisorba officinalis, 10-30 parts of sanguisorba officinalis charcoal, 10-30 parts of aconite, and 0.5-1.5 parts of borneol.
2. A pharmaceutical composition for treating burns and scalds, characterized in that: Calculated by weight, the raw materials include 15-25 parts of rhubarb, 15-25 parts of rhubarb charcoal, 15-25 parts of sanguisorba officinalis, 15-25 parts of sanguisorba officinalis charcoal, 15-25 parts of aconite, and 0.8-1.2 parts of borneol.
3. A pharmaceutical composition for treating burns and scalds, characterized in that: Calculated by weight, the raw materials include 20 parts of rhubarb, 20 parts of rhubarb charcoal, 20 parts of sanguisorba officinalis, 20 parts of sanguisorba officinalis charcoal, 20 parts of aconite, and 1 part of borneol.
4. The method for preparing the pharmaceutical composition for treating burns and scalds according to any one of claims 1 to 3, characterized in that: The following steps are involved: Weigh rhubarb, rhubarb charcoal, sanguisorba officinalis, sanguisorba officinalis charcoal, aconite and borneol according to proportion, grind into powder; add auxiliary materials to make a thick paste.
5. The preparation method according to claim 4, characterized in that: The auxiliary material is sesame oil.
6. Use of the pharmaceutical composition for treating burns and scalds according to any one of claims 1 to 3 in the preparation of medicines for treating burns and scalds.
7. Use of the pharmaceutical composition for treating burns and scalds according to any one of claims 1 to 3 in the preparation of a drug for promoting the healing of burn and scald wounds.